Panelists discuss how healthcare resource utilization is primarily driven by hospitalizations, medication costs, and ...

Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.

PAH patients with cardiovascular disease risk had similar hospitalization and mortality rates as those without after a ...

In this high-yield, clinically focused session, Dr. Steven L. Cohn, one of the leading experts in perioperative medicine, ...

Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted priority review for its request ...

Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair ...

Other causes of PAA include pulmonary hypertension, vasculitis, syphilis, tuberculosis, left-to-right shunts, pulmonary valve stenosis with post-stenotic dilatation, vasa vasorum dysfunction, trauma, ...

Pulmonary arterial hypertension (PAH) is a rare disease in which the arteries of the lungs present with high blood pressure. 1 Pulmonary hypertension (PH) is defined as a mean pulmonary arterial ...

References: Backes CH, Hill KD, Shelton EL, et al. Patent ductus arteriosus: a contemporary perspective for the pediatric and adult cardiac care provider. J Am Heart Assoc. 2022;11 (17):e025784 ...